Neurocognitive change observed in the CHARTER HIV cohort could be due to chance, and may be a cause as well as a consequence of detectable viremia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Metabolic Syndrome and Cardiovascular Disease Impacts on the Pathophysiology and Phenotype of HIV-Associated Neurocognitive Disorders.Current topics in behavioral neurosciences · 2021
   Review
2. Reply to Haddow et al.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
   Article

Corrections and comments

• Commented on by
  Reply to Haddow et al.2015
• Comment on
  Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.2015

Authors and funding

5 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as